HomeAI · summaries
Storia in 2 fonti
ASCO26: BMS and J&J debut shining multiple myeloma data - Pharmaceutical Technology
Both BMS and J&J touted positive data for their multiple myeloma drugs at ASCO 2026.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
pharmaceutical-technology.com
ASCO26: BMS and J&J debut shining multiple myeloma data - Pharmaceutical Technology
Both BMS and J&J touted positive data for their multiple myeloma drugs at ASCO 2026.
- ·
ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise
A number of companies presented new data on their cancer vaccine candidates at ASCO 2026.
- ·
ynetnews.com
Breakthrough offers new hope for patients with relapsed blood cancer
Two late-stage trials presented at ASCO show major advances for patients with relapsed multiple myeloma, including an oral drug that doubled disease-control time and an…